FLORIDA — The Biden Administration is taking over the distribution of monoclonal antibody infusion treatment for COVID-19 as demand increases in order to avoid shortages.

What You Need To Know

  • The U.S. Health and Human Services said seven southern states, including Florida, have accounted for 70% of orders

  • Monoclonal antibody treatment is used to help already sick people avoid serious illness from COVID-19

  • Gov. Ron DeSantis has been pushing the treatment across Florida for months

The U.S. Health and Human Services (HHS) figures show Florida ranks No. 1 in doses in the past week at 30,000.

Florida Gov. Ron DeSantis said part of the reason the state has gone through so much of the treatment is that he has made it a priority and it has saved lives.

The governor has come under fire because a big DeSantis donor has a large stake in Regeneron, a primary company that makes these treatments, according to the Associated Press.

Monoclonal antibodies are man-made and work with the body's immune system to prevent severe illness.

The Biden administration has contracted with Regeneron for nearly 1.5 million more doses nationwide.

HHS will allocate to states each week, rather than administration sites ordering them directly, CNN is reporting.

"We've been thrown a major curveball here with a really huge cut from HHS and the Biden administration, even though you see the numbers," DeSantis said. "We're all very happy where we are today versus where we were a month ago, much better trends, and we've kept a lot of people out of the hospital."

HHS officials said they are taking over administration of allocation of the doses to maintain equal distribution over the coming weeks to states across the country.

The governor said this is going to cause a major disruption in Florida, but his administration is going to work hard to overcome it and make sure people who want the treatment can get it.

Regeneron will supply the treatment for $2,100 per dose to the government.

The government will continue to provide it free to patients.